• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
SNSE

SNSE

Sensei Biotherapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD15.85

-0.25 (-1.55%)

Rating:B-

Company Profile

CEO

Christopher W. Gerry

IPO Date

2021-02-04

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$16.95

Prev. Close

$16.09

Day Low

$15.31

Day High

$18.19

52W Low

$5.60

52W High

$36.76

Market Cap

$0.02B

Volume

0.04M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

35.0%

Avg Negative

3.8%

Avg Neutral

61.5%

News Feed

These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday

The Motley Fool·6/29/2021·↓ negative

Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs

GlobeNewsWire·6/28/2021·↑ positive

5 Stocks With High Guru and Insider Buys in the Past 3 Months

GuruFocus·6/9/2021·↑ positive

Sensei Biotherapeutics (SNSE) Stock: 30.11% Increase Explanation

Pulse2·5/20/2021·↑ positive

Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck

GlobeNewsWire·5/19/2021·↑ positive

Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update

GlobeNewsWire·5/12/2021·↑ positive

Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D.

GlobeNewsWire·5/5/2021·↓ negative

Sensei Biotherapeutics Appoints Jessie M. English, Ph.D.

GlobeNewsWire·4/5/2021·↑ positive

Sensei Biotherapeutics to Present at Oppenheimer 31st Annual Virtual Healthcare Conference

GlobeNewsWire·3/9/2021·↑ positive

Sensei Biotherapeutics Announces Closing of Initial Public Offering

GlobeNewsWire·2/10/2021·↑ positive